BLFS

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 6

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,538

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 5

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,538

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 3

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,538

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-008953 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,679

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months.

F2 · balance_after: The amount reported in Column 5 on Table I in the Form 4 filed by the reporting person on April 1, 2021 was incorrect by a deficit of 6,338 due to a typographical error.

SEC source: 0001437749-21-008952 · rdgdoc.xml · nonDerivative · entry 1

DuRoss Amy · CIK 0001854968 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-21-008951 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,648

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months.

SEC source: 0001437749-21-008950 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,014

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months.

SEC source: 0001437749-21-008949 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,538

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months.

SEC source: 0001437749-21-008948 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,566

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months.

SEC source: 0001437749-21-008947 · rdgdoc.xml · nonDerivative · entry 1

Ellingson Rachel · CIK 0001557271 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date.

SEC source: 0001437749-21-008759 · rdgdoc.xml · derivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,382

Underlying: Common Stock · 11,461 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019.

SEC source: 0001437749-21-008759 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,527

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.92 to $35.66, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-008759 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,988

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-008758 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,795

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.75 to $35.78, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-008332 · rdgdoc.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,794

F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-008332 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-21-008331 · rdgdoc.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,981

F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-008331 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-21-008330 · rdgdoc.xml · nonDerivative · entry 2

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,204

F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-008330 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-21-008329 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,316

F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-008329 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-21-008328 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,527

F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-008328 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,676

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-21-007721 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,981

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-007720 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,411

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-007719 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,522

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-007718 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,239

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-007717 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,750

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 9

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 6

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,132

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $38.65, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 5

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-007081 · rdgdoc.xml · derivative · entry 6

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,707

Underlying: Common Stock · 10,000 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.

SEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 4

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,997

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $41.95, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 3

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 8

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,132

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $41.95, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 3

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 7

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,132

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.3 to $46.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-007081 · rdgdoc.xml · derivative · entry 5

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,707

Underlying: Common Stock · 10,000 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.

SEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,997

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $39.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007081 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-21-007080 · rdgdoc.xml · derivative · entry 3

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,657

Underlying: Common Stock · 16,332 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On December 20, 2016, the reporting person was granted an option to purchase 163,323 shares of common stock which vested in two equal installments on March 8, 2018 and March 8, 2019.

SEC source: 0001437749-21-007080 · rdgdoc.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,973

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $38.33 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-21-007080 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.